secwatch.observer — SEC 8-K summary
======================================

Issuer:     Ainos, Inc. (AIMD)
CIK:        0001014763
Form:       8-K
Filed at:   2023-11-13T23:59:59+00:00
Accession:  0001654954-23-014166
Event type: earnings
Sentiment:  negative
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ainos Q3 2023 revenue drops 98.6% to $24.5K; net loss narrows to $3.0M
----------------------------------------------------------------------

- Revenue fell to $24,489 from $1,757,774 in Q3 2022 due to COVID-19 test kit demand decline.
- Gross profit turned negative ($63,384) vs positive $581,742 YoY on lower sales and inventory loss.
- Net loss narrowed to $2.97M from $7.82M YoY, helped by lower operating expenses.
- Cash and equivalents $2.37M as of Sept 30, 2023; company secured $3M of planned $10M private placement.
- VELDONA Pet launched in Taiwan (300k units shipped); FDA orphan drug designation for VELDONA for oral warts.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1014763/000165495423014166/0001654954-23-014166-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1014763/000165495423014166/aimd_8k.htm
  HTML page:      https://secwatch.observer/filing/0001654954-23-014166

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer